LeMaitre Vascular, Inc. $LMAT Shares Purchased by Thrivent Financial for Lutherans

Thrivent Financial for Lutherans increased its stake in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 492.0% in the 4th quarter, HoldingsChannel reports. The firm owned 88,950 shares of the medical instruments supplier’s stock after buying an additional 73,925 shares during the quarter. Thrivent Financial for Lutherans’ holdings in LeMaitre Vascular were worth $7,214,000 at the end of the most recent reporting period.

Other institutional investors have also recently modified their holdings of the company. Cornerstone Planning Group LLC raised its position in shares of LeMaitre Vascular by 534.0% during the 3rd quarter. Cornerstone Planning Group LLC now owns 336 shares of the medical instruments supplier’s stock worth $30,000 after purchasing an additional 283 shares during the last quarter. MAI Capital Management acquired a new position in shares of LeMaitre Vascular during the 3rd quarter worth approximately $38,000. Geneos Wealth Management Inc. raised its position in shares of LeMaitre Vascular by 250.3% during the 1st quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier’s stock worth $47,000 after purchasing an additional 398 shares during the last quarter. EverSource Wealth Advisors LLC acquired a new position in LeMaitre Vascular in the 2nd quarter valued at $47,000. Finally, GAMMA Investing LLC raised its holdings in LeMaitre Vascular by 32.7% in the 4th quarter. GAMMA Investing LLC now owns 727 shares of the medical instruments supplier’s stock valued at $59,000 after acquiring an additional 179 shares during the last quarter. 84.64% of the stock is currently owned by institutional investors and hedge funds.

LeMaitre Vascular Stock Up 0.1%

Shares of NASDAQ LMAT opened at $101.43 on Thursday. LeMaitre Vascular, Inc. has a 52-week low of $78.35 and a 52-week high of $118.01. The firm has a fifty day moving average of $108.94 and a 200-day moving average of $95.20. The stock has a market capitalization of $2.32 billion, a PE ratio of 37.43, a P/E/G ratio of 2.81 and a beta of 0.60. The company has a quick ratio of 12.20, a current ratio of 14.32 and a debt-to-equity ratio of 0.42.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings data on Tuesday, May 5th. The medical instruments supplier reported $0.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.66 by $0.02. LeMaitre Vascular had a net margin of 24.35% and a return on equity of 15.36%. The company had revenue of $66.55 million during the quarter, compared to analysts’ expectations of $66.67 million. During the same period in the previous year, the company earned $0.48 EPS. The business’s quarterly revenue was up 11.1% compared to the same quarter last year. LeMaitre Vascular has set its FY 2026 guidance at 2.930-3.080 EPS and its Q2 2026 guidance at 0.790-0.840 EPS. On average, analysts anticipate that LeMaitre Vascular, Inc. will post 3 EPS for the current year.

LeMaitre Vascular Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 4th. Stockholders of record on Thursday, May 21st will be paid a dividend of $0.25 per share. The ex-dividend date of this dividend is Thursday, May 21st. This represents a $1.00 annualized dividend and a dividend yield of 1.0%. LeMaitre Vascular’s payout ratio is currently 36.90%.

Insider Activity at LeMaitre Vascular

In related news, Director Bridget A. Ross sold 5,044 shares of the company’s stock in a transaction on Thursday, May 7th. The shares were sold at an average price of $111.10, for a total transaction of $560,388.40. Following the completion of the sale, the director directly owned 3,942 shares of the company’s stock, valued at approximately $437,956.20. This represents a 56.13% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Trent G. Kamke sold 2,928 shares of the company’s stock in a transaction on Friday, May 8th. The stock was sold at an average price of $107.00, for a total transaction of $313,296.00. Following the sale, the insider directly owned 3,749 shares of the company’s stock, valued at approximately $401,143. This trade represents a 43.85% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 269,891 shares of company stock valued at $28,969,086 over the last quarter. 7.40% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several brokerages have weighed in on LMAT. Barrington Research boosted their price target on LeMaitre Vascular from $105.00 to $120.00 and gave the company an “outperform” rating in a report on Wednesday, May 6th. Weiss Ratings downgraded LeMaitre Vascular from a “buy (b)” rating to a “buy (b-)” rating in a report on Wednesday, May 6th. Freedom Capital upgraded LeMaitre Vascular to a “hold” rating in a report on Tuesday, March 31st. Roth Mkm reiterated a “buy” rating and issued a $117.00 price target (up from $108.00) on shares of LeMaitre Vascular in a report on Thursday, February 26th. Finally, Citizens Jmp boosted their price target on LeMaitre Vascular from $118.00 to $127.00 and gave the company a “market outperform” rating in a report on Wednesday, May 6th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $112.60.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.